MA55069A - Nouvelles protéines de fusion spécifique à cd137 et gpc3 - Google Patents
Nouvelles protéines de fusion spécifique à cd137 et gpc3Info
- Publication number
- MA55069A MA55069A MA055069A MA55069A MA55069A MA 55069 A MA55069 A MA 55069A MA 055069 A MA055069 A MA 055069A MA 55069 A MA55069 A MA 55069A MA 55069 A MA55069 A MA 55069A
- Authority
- MA
- Morocco
- Prior art keywords
- gpc3
- fusion proteins
- proteins specific
- new fusion
- new
- Prior art date
Links
- 102100032530 Glypican-3 Human genes 0.000 title 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000100 | 2019-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55069A true MA55069A (fr) | 2022-01-05 |
Family
ID=65685094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055069A MA55069A (fr) | 2019-02-26 | 2020-02-25 | Nouvelles protéines de fusion spécifique à cd137 et gpc3 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12486330B2 (enExample) |
| EP (1) | EP3931209A1 (enExample) |
| JP (1) | JP7476219B2 (enExample) |
| KR (1) | KR20210133254A (enExample) |
| CN (1) | CN113474359B (enExample) |
| AU (1) | AU2020229436B2 (enExample) |
| BR (1) | BR112021016829A2 (enExample) |
| CA (1) | CA3124441A1 (enExample) |
| IL (1) | IL284687B2 (enExample) |
| MA (1) | MA55069A (enExample) |
| MX (1) | MX2021010039A (enExample) |
| SG (1) | SG11202106353VA (enExample) |
| WO (1) | WO2020173897A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020253034A1 (en) * | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| MX2023011775A (es) * | 2021-04-05 | 2023-11-29 | Cytovia Therapeutics Llc | Anticuerpos biespecificos dirigidos a nkp46 y gpc3 y metodos de uso de los mismos. |
| IL307923A (en) * | 2021-04-23 | 2023-12-01 | Shanghai Henlius Biotech Inc | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| WO2022242682A1 (en) * | 2021-05-21 | 2022-11-24 | Beigene, Ltd. | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use |
| EP4386007A1 (en) * | 2021-08-12 | 2024-06-19 | Shanghai TTM-BIO Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
| CN115960242B (zh) * | 2021-09-09 | 2023-10-17 | 广东东阳光药业股份有限公司 | 抗癌结合分子及其应用 |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| CN113912699A (zh) * | 2021-10-14 | 2022-01-11 | 江南大学 | 一种新型治疗乳腺癌的fgf类似物及其应用 |
| CN116640224A (zh) * | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Cd137抗体和cd40l的融合蛋白及其应用 |
| TWI864640B (zh) * | 2022-03-18 | 2024-12-01 | 大陸商映恩生物製藥（蘇州）有限公司 | Gpc3抗體藥物偶聯物及其用途 |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| CN119613552B (zh) * | 2024-07-23 | 2025-11-28 | 艾可泰科(浙江)控股有限公司 | 一组抗人gpc3纳米抗体突变体及嵌合抗原受体和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| JP5608368B2 (ja) | 2006-08-01 | 2014-10-15 | ピエリス アーゲー | 涙リポカリンの突然変異タンパク質およびそれを得るための方法 |
| RU2010116756A (ru) * | 2007-09-28 | 2011-11-10 | Чугаи Сейяку Кабусики Кайся (Jp) | Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме |
| PH12020550156A1 (en) * | 2010-09-09 | 2024-01-15 | Pfizer | 4-1bb binding molecules |
| WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| US9266959B2 (en) * | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| WO2016177802A1 (en) * | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| CA2980839C (en) * | 2015-05-04 | 2024-09-10 | Pieris Pharmaceuticals Gmbh | CD137 SPECIFIC PROTEINS |
| RU2754466C2 (ru) * | 2015-05-18 | 2021-09-02 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| CA2982034A1 (en) * | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| US20200040084A1 (en) | 2017-01-06 | 2020-02-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| EP3638700B8 (en) | 2017-06-14 | 2024-09-04 | Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation | Proteinaceous heterodimer and use thereof |
-
2020
- 2020-02-25 BR BR112021016829-0A patent/BR112021016829A2/pt unknown
- 2020-02-25 KR KR1020217030737A patent/KR20210133254A/ko active Pending
- 2020-02-25 MA MA055069A patent/MA55069A/fr unknown
- 2020-02-25 MX MX2021010039A patent/MX2021010039A/es unknown
- 2020-02-25 SG SG11202106353VA patent/SG11202106353VA/en unknown
- 2020-02-25 US US17/433,155 patent/US12486330B2/en active Active
- 2020-02-25 JP JP2021549919A patent/JP7476219B2/ja active Active
- 2020-02-25 CA CA3124441A patent/CA3124441A1/en active Pending
- 2020-02-25 WO PCT/EP2020/054821 patent/WO2020173897A1/en not_active Ceased
- 2020-02-25 EP EP20705382.8A patent/EP3931209A1/en active Pending
- 2020-02-25 CN CN202080016379.9A patent/CN113474359B/zh active Active
- 2020-02-25 AU AU2020229436A patent/AU2020229436B2/en active Active
-
2021
- 2021-07-07 IL IL284687A patent/IL284687B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7476219B2 (ja) | 2024-04-30 |
| SG11202106353VA (en) | 2021-07-29 |
| BR112021016829A2 (pt) | 2021-10-19 |
| US12486330B2 (en) | 2025-12-02 |
| KR20210133254A (ko) | 2021-11-05 |
| CN113474359B (zh) | 2025-02-21 |
| EP3931209A1 (en) | 2022-01-05 |
| JP2022523524A (ja) | 2022-04-25 |
| CN113474359A (zh) | 2021-10-01 |
| MX2021010039A (es) | 2021-09-21 |
| US20220153864A1 (en) | 2022-05-19 |
| AU2020229436A1 (en) | 2021-07-01 |
| WO2020173897A1 (en) | 2020-09-03 |
| AU2020229436B2 (en) | 2024-12-19 |
| IL284687A (en) | 2021-08-31 |
| IL284687B2 (en) | 2025-11-01 |
| CA3124441A1 (en) | 2020-09-03 |
| IL284687B1 (en) | 2025-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55069A (fr) | Nouvelles protéines de fusion spécifique à cd137 et gpc3 | |
| IL281783A (en) | Sirpα binding proteins and methods of use thereof | |
| DK3830120T3 (da) | Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1 | |
| EP3717505A4 (en) | GENENICALLY MODIFIED DNA-BINDING PROTEINS | |
| HUE065725T2 (hu) | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások | |
| EP3810172A4 (en) | Heterodimeric proteins and uses thereof | |
| DK3265478T3 (da) | Fusionsproteiner, der omfatter et bindingsprotein og et interleukin-15-polypeptid med reduceret affinitet til il15ra, og terapeutiske anvendelser deraf | |
| MA53883A (fr) | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations | |
| EP3735458A4 (en) | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF | |
| EP3746103A4 (en) | PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2 | |
| DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
| DK4073098T3 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| EP3950720A4 (en) | Fusion protein and use thereof | |
| HRP20192173T8 (hr) | Ekspresija rekombinantnih proteina u kukuljicama vrste trichoplusia ni | |
| IL289979A (en) | Methods of quantifying frataxin and frataxin fusion proteins | |
| DK3380119T3 (da) | Fmdv- og e2-fusionsproteiner og anvendelser deraf | |
| EP4065597A4 (en) | LONG-ACTING GDF15 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION THEREFROM | |
| EP4190803A4 (en) | SIRPa-FC FUSION PROTEIN | |
| EP4083055A4 (en) | Sugar-modified protein | |
| EP3829622A4 (en) | DOUBLE AGONIST FUSION PROTEINS | |
| EP3811291A4 (en) | Guide-assisted capture of material data | |
| MA48777A (fr) | Nouvelles protéines de liaison à un antigène | |
| EP3740501A4 (en) | FUSION PROTEIN EXTENSIONS | |
| EP4084820A4 (en) | Fusion proteins and methods of use thereof | |
| EP4077680A4 (en) | DETECTION OF NEW DEGRADATION-RELATED INTERACTIONS |